about
ERAP75 functions as a coactivator to enhance estrogen receptor alpha transactivation in prostate stromal cellsDOK2 inhibits EGFR-mutated lung adenocarcinoma.In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes.Generation and characterization of a complete null estrogen receptor alpha mouse using Cre/LoxP technology.Loss of epithelial oestrogen receptor α inhibits oestrogen-stimulated prostate proliferation and squamous metaplasia via in vivo tissue selective knockout modelsReduced prostate branching morphogenesis in stromal fibroblast, but not in epithelial, estrogen receptor α knockout miceDesigner monotransregulators provide a basis for a transcriptional therapy for de novo endocrine-resistant breast cancer.Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.RRR-alpha-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects.Endosome and INPP4B.Pills of PTEN? In and out for tumor suppression.Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms.Preclinical and Coclinical Studies in Prostate Cancer.An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer.Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism.The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function.Loss of LDAH associated with prostate cancer and hearing lossSPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression.The therapeutic and preventive effect of RRR-alpha-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3The functions and regulation of the PTEN tumour suppressor: new modes and prospectsAbi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signalingThe expanded role of fatty acid metabolism in cancer: new aspects and targetsVulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapyReactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathwayInterplay between c-Src and the APC/C co-activator Cdh1 regulates mammary tumorigenesisCompound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis
P50
Q28115023-FF7ACB4D-5100-47EE-B949-566C539BB6A8Q35047411-E24F1910-3773-4816-B6DA-37F43BE442F6Q35836418-D9C32797-1CB4-4C60-9152-3812C2E16D8EQ36418639-964C8FCC-FF81-492F-B809-0CF6DF76E3FEQ36819484-B7384B8C-40DD-4B55-AF7C-AD2D03A5915AQ37044256-33F44289-3992-446E-8F33-E9FDF5886261Q37430548-3C158DAB-83F4-4137-B0C9-5F71A0B35AB9Q38912800-25904DB4-5789-4945-AC3D-A2466331DF5EQ38991113-9D9AFC54-2005-4881-8D36-E68BCDDB8CE7Q39899583-884523BA-2273-4F36-A2CB-35BB71685847Q42934435-5D8A55A1-CB8C-4DA2-8361-B70542D48614Q42957720-AB6A12BE-D088-41B9-9CA9-9F902A4CDBCDQ47198804-6E5BA931-AC96-43C6-8A28-05D3CF9775ADQ47893779-4D7F0FBD-02B3-40C5-B113-260B374845ADQ48239804-F453D7CC-8F5F-463E-98CD-4D916DBBB54DQ48240280-B18AB2AE-F422-4A30-ACC3-CED1411B1AE6Q51013762-E2979B6C-E3F4-4B27-B99A-77187106B639Q62494148-C67A72EC-7E81-4281-93A4-B459A74C94C4Q64947175-166D5451-5A62-45B3-8FEF-3B1AA083C3FDQ80087660-84E80BB4-275C-45D3-9232-3889FB3D636BQ88955683-414B999B-0C5E-4B40-9AAB-CB24B70BD857Q90146243-8DEA0818-C52D-42E4-BCF8-1EC9458C30B9Q90620365-67DEF936-BCDA-449A-8217-141B954E0FC4Q91525342-F583B8AB-0357-494B-9D51-054DA9FCD9C2Q92090098-8844DA87-282A-4B6D-A368-3201B4598A35Q92668610-406D943C-B185-4081-8374-65FE2B7D61C5Q93365387-19ECD313-57E0-40D2-88A6-6BC6D4289E6B
P50
description
researcher ORCID: 0000-0002-3470-1062
@en
name
Ming Chen
@ast
Ming Chen
@en
Ming Chen
@es
Ming Chen
@nl
type
label
Ming Chen
@ast
Ming Chen
@en
Ming Chen
@es
Ming Chen
@nl
prefLabel
Ming Chen
@ast
Ming Chen
@en
Ming Chen
@es
Ming Chen
@nl
P106
P31
P496
0000-0002-3470-1062